Baird analyst Joel Beatty lowered the firm’s price target on BeyondSpring to $4 from $11 and keeps an Outperform rating on the shares. The analyst said the target reduction comes after BeyondSpring confirmed that the NDA filing for plinabulin to treat chemotherapy-induced neutropenia has been withdrawn in China.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BYSI: